Novartis hires Dana-Farber's Bradner; Glaxo vacates, sells NC lab;


@FiercePharma: Toxin from sea algae impacts memory, behavior in California sea lions: Study. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Mylan wants some payback for plants it bought from Strides that have been cited by FDA. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: AstraZeneca shrugs off pharma's emerging markets slowdown, but Lilly's suffering. Article | Follow @CarlyHFierce

> Novartis ($NVS) has brought on James Bradner of Harvard's Dana-Farber Cancer Institute to head its Institutes for Biomedical Research. Report

> GlaxoSmithKline ($GSK) has vacated a lab building at Imperial Center in Durham and sold the property to a real estate investor for $10 million. Report

> Massachusetts has approved a tax break tallying $7 million-plus to offer Alnylam ($ALNY) if it builds a $100 million manufacturing plant there. Report

> Novo Nordisk ($NVO) says its Phase IIIa trial of diabetes hopeful semaglutide has hit its objective. Report

> German airline Lufthansa is playing down rumors that it could get a new chairman after Merck KGaA CEO Karl-Ludwig Kley said he would accept the job if he were offered it. Report

Medical Device News

@FierceMedDev: NYU researchers roll out ResearchKit app as part of concussion-monitoring study. Article | Follow @FierceMedDev

@EmilyWFierce: In this week's Dx Digest, $ILMN makes waves in China and $LH buys a women's health lab. More | Follow @EmilyWFierce

> VA signs onto ReWalk Robotics' exoskeleton device for paralyzed veterans. Report

> Australian teams aims to create dialysis-like blood filtration system to treat cancer. Article

> Startup touts first-in-man study of its sensor for cardiac ablation catheters in hopes of partnership. Story

Biotech News

@FierceBiotech: Biotech bad boy Martin Shkreli faces a new set of angry foes: federal prosecutors. News | Follow @FierceBiotech

@JohnCFierce: Gilead steps in to replace AbbVie with $2B Galapagos collaboration. News | Follow @JohnCFierce

@DamianFierce: it is with solemn humility that I now accept the mantle of Biotech's Bad Boy. thank you. | Follow @DamianFierce

> AstraZeneca bets $7B on Acerta's potential blockbuster cancer treatment. Report

> Kahr Medical leans on Korean VCs to raise $12M for oncology R&D. Story

> University of California commits $250M for a new tech venture fund for biotech, more. Article

CRO News

> PPD reportedly on the block for $8B. Report

> Recipharm signs on to manufacture an in-development cancer drug, investing in a Swedish biotech. Article

> On the rebound, AMRI trades $52M for a testing firm. News

Pharma Manufacturing News

> AstraZeneca shifts supply chain strategy from air to sea freight shipments. Report

> GSK opens Australia pilot plant to test blow-fill-seal technology on vaccines. Article

> WuXi and PRA canceling joint venture in China. Item

> Deadline looms to meet new label and insert requirements in Taiwan. More

> WuXi to sell AstraZeneca China's largest biologics plant for $100M. News

Pharma Asia News

> Indian healthcare IPOs raise $300M. Item

> Don't count India out yet in biosimilars race, Quintiles exec says. More

> YiChang IPO joins other drug companies in tough IPO market. Report

> Taiwan sets June 2016 deadline on new packaging, insert rules. Story

> WuXi venture unit raises $290M for 'find in U.S., build in China' venture fund. Article

And Finally... China's drug regulator is set to strengthen oversight of clinical trials of new drugs. More